[ Price : $8.95]
Two Hyman, Phelps & McNamara attorneys say FDA may give research-use-only products greater regulatory scrutiny as a way to maintai...[ Price : $8.95]
CBER director Vinay Prasad outlines his expectations for advancing rare disease products, such as embracing both surrogate endpoin...[ Price : $8.95]
FDA approves a Bayer Healthcare Pharmaceuticals supplemental NDA for Nubega (darolutamide) for metastatic castration-sensitive pro...[ Price : $8.95]
FDA accepts for priority review a Kura Oncology NDA for ziftomenib, a potential new treatment for certain adult patients with rela...[ Price : $8.95]
FDA gives de novo authorization to Clarity Breast which uses artificial intelligence to make a five-year breast cancer risk predic...[ Price : $8.95]
FDA deputy commissioner for strategic initiatives Lowell M. Zeta adds Special Counsel for FDA role to his duties.[ Price : $8.95]
Congressman Jason Crow (D-CO) leads a bipartisan group of lawmakers in a push to significantly expand federal funding for Amyotrop...[ Price : $8.95]
A new combination therapy involving AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) and pertuzumab (Genentechs Pe...